Agilent Completes $240 Million Proscia Acquisition

The deal adds Proscia's digital pathology software to Agilent's diagnostics portfolio, with an additional $30 million payable on future milestones.

Updated on Nov. 4, 2026 in Healthcare

Clean laboratory bench with a brass-and-glass microscope beside an unlabeled glass slide under soft daylight. — Agilent Technologies completed its $240 million cash acquisition of Philadelphia-based digital pathology software maker Proscia, with another $30 million payable on future milestones. AI Illustration. Upload story photo >

Agilent Technologies has completed its acquisition of Proscia, a Philadelphia-based digital pathology software company, for $240 million in cash at closing. The deal follows Agilent's separate agreement to acquire Biocare Medical for $950 million in cash.

Why it matters

The acquisition expands Agilent's presence in digital pathology and companion diagnostics, a segment that relies on software to analyze tissue images for clinical use. It also reflects continued consolidation among diagnostics companies seeking AI-enabled tools.

Agilent paid $240 million in cash at closing, with up to $30 million more tied to future performance, against Proscia's trailing 12-month revenue of more than $18 million. Proscia's Concentriq software serves more than 4,000 laboratories, hospitals and clinics, but the timing and likelihood of the additional milestone payments were not disclosed.

The players

Agilent Technologies

Santa Clara, California-based life sciences and diagnostics company with fiscal 2025 revenue of $6.95 billion, which is expanding its digital pathology and companion diagnostics offerings.

Proscia

Philadelphia-based digital pathology software company founded in 2014 whose Concentriq platform supports tissue image analysis for clinical and research use.

The details

Proscia's Concentriq software, which received FDA 510(k) clearance for primary diagnosis in February 2024, is now part of Agilent's Life Sciences and Diagnostics Markets Group. Agilent had targeted a closing early in its fiscal 2027, which began Nov. 1.

Sept. 2022: Agilent signed a multiyear distribution agreement with Proscia.
Feb. 2024: Concentriq AP-Dx received FDA 510(k) clearance for primary diagnosis.
March 2025: Proscia raised $50 million in a round led by Insight Partners.
March 9, 2026: Agilent agreed to acquire Biocare Medical for $950 million.
Oct. 13, 2026: Agilent announced the Proscia deal.

Market Landscape

The deal reflects consolidation in clinical pathology software, where Proscia's Concentriq AP-Dx received FDA 510(k) clearance for primary diagnosis in February 2024. Agilent's move positions it to compete more directly in digital pathology as it pairs Proscia with its recent $950 million agreement to acquire Biocare Medical.

For clinicians and labs using Proscia's software, the deal may affect product roadmaps and support as it becomes part of Agilent. Customers relying on Concentriq for diagnostic workflows should watch for any changes to pricing, integration, or service arrangements under the new ownership.

The takeaway

Diagnostics deals increasingly hinge on software that supports clinical decisions, so labs evaluating digital pathology tools should track ownership changes and product commitments. Watching how Agilent integrates Proscia will show whether the acquisition delivers the AI-enabled benefits it has projected.